Department of Medicine, University of Louisville, Louisville, Kentucky, 40202, USA.
James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, 40202, USA.
AAPS J. 2017 Nov;19(6):1691-1702. doi: 10.1208/s12248-017-0154-9. Epub 2017 Oct 18.
Exosomes are extracellular microvesicles with a particle size of 30-100 nm and carry a cargo of proteins, lipids, RNA, and DNA. Their properties of shuttling in-and-out of the cells suggest that these particles can be exploited as a nano drug carrier. In this manuscript, we show that curcumin can be delivered effectively using milk-derived exosomes. Curcumin when mixed with exosomes in the presence of 10% ethanol:acetonitrile (1:1) provided a drug load of 18-24%, and the formulation stored at - 80°C was stable for 6 months as determined by particle size analysis, drug load, and antiproliferative activity. The uptake of exosomes by cancer cells involved caveolae/clathrin-mediated endocytosis. Oral administration of exosomal curcumin (ExoCUR) in Sprague-Dawley rats demonstrated 3-5 times higher levels in various organs versus free agent. ExoCUR showed enhanced antiproliferative activity against multiple cancer cell lines including, breast, lung, and cervical cancer compared with the free curcumin. ExoCUR showed significantly higher anti-inflammatory activity measured as NF-κB activation in human lung and breast cancer cells. To determine in vivo antitumor activity, nude mice bearing the cervical CaSki tumor xenograft were treated with ExoCUR by oral gavage, curcumin diet, exosomes alone, and PBS as controls. While curcumin via dietary route failed to elicit any effect, exosomes had a modest (25-30%) tumor growth inhibition. However, ExoCUR showed significant inhibition (61%; p < 0.01) of the cervical tumor xenograft. No gross or systemic toxicity was observed in the rats administered with the exosomes or ExoCUR. These results suggest that exosomes can be developed as potential nano carriers for delivering curcumin which otherwise has encountered significant tissue bioavailability issues in the past.
外泌体是一种具有 30-100nm 粒径的细胞外微囊泡,携带蛋白质、脂质、RNA 和 DNA 等货物。它们在细胞内外穿梭的特性表明,这些颗粒可以被用作纳米药物载体。在本手稿中,我们表明姜黄素可以通过乳源外泌体有效地递送到细胞内。当姜黄素与外泌体在 10%乙醇:乙腈(1:1)存在下混合时,提供了 18-24%的药物负载,并且通过粒径分析、药物负载和抗增殖活性确定,在-80°C 下储存 6 个月是稳定的。外泌体被癌细胞摄取涉及网格蛋白/小窝蛋白介导的内吞作用。在 Sprague-Dawley 大鼠中口服外泌体姜黄素(ExoCUR),与游离药物相比,在各种器官中的水平高 3-5 倍。与游离姜黄素相比,ExoCUR 对多种癌细胞系(包括乳腺癌、肺癌和宫颈癌)表现出增强的抗增殖活性。ExoCUR 表现出更高的抗炎活性,以人肺癌和乳腺癌细胞中的 NF-κB 激活来衡量。为了确定体内抗肿瘤活性,用外泌体通过口服灌胃、姜黄素饮食、外泌体单独和 PBS 作为对照处理携带宫颈 CaSki 肿瘤异种移植物的裸鼠。虽然通过饮食途径给予姜黄素没有产生任何效果,但外泌体对肿瘤生长的抑制作用适中(25-30%)。然而,ExoCUR 对宫颈肿瘤异种移植物的抑制作用显著(61%;p<0.01)。给予外泌体或 ExoCUR 的大鼠没有观察到明显的全身或系统毒性。这些结果表明,外泌体可以被开发为潜在的纳米载体,用于输送姜黄素,而姜黄素在过去遇到了显著的组织生物利用度问题。